Company Analysis Santen Pharmaceutical Co., Ltd.
1. Summary
Advantages
- Dividends (3.27%) are higher than the sector average (2.87%).
- The company's current efficiency (ROE=8.88%) is higher than the sector average (ROE=1.13%)
Disadvantages
- Price (1590.5 Β₯) is higher than fair price (870.49 Β₯)
- The stock's return over the last year (-0.1886%) is lower than the sector average (0%).
- Current debt level 8.07% has increased over 5 years from 1.04%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Santen Pharmaceutical Co., Ltd. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 4.9% | 0% | 0.2% |
| 90 days | 12.2% | 6.1% | 2.1% |
| 1 year | -0.2% | 0% | -2.3% |
4536 vs Sector: Santen Pharmaceutical Co., Ltd. has slightly underperformed the "Healthcare" sector by -0.1886% over the past year.
4536 vs Market: Santen Pharmaceutical Co., Ltd. has outperformed the market by 2.1% over the past year.
Stable price: 4536 is not significantly more volatile than the rest of the market on "Tokyo Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 4536 with weekly volatility of -0.0036% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (1590.5 Β₯) is higher than the fair price (870.49 Β₯).
Price is higher than fair: The current price (1590.5 Β₯) is 45.3% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (20.55) is lower than that of the sector as a whole (112.46).
P/E vs Market: The company's P/E (20.55) is lower than that of the market as a whole (138.33).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.79) is lower than that of the sector as a whole (70.29).
P/BV vs Market: The company's P/BV (1.79) is lower than that of the market as a whole (107.9).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.81) is lower than that of the sector as a whole (75.53).
P/S vs Market: The company's P/S indicator (1.81) is lower than that of the market as a whole (108.73).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (8.64) is lower than that of the sector as a whole (29.26).
EV/Ebitda vs Market: The company's EV/Ebitda (8.64) is lower than that of the market as a whole (109.28).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 2.56% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (2.56%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-1.09%).
5.4. ROE
ROE vs Sector: The company's ROE (8.88%) is higher than that of the sector as a whole (1.13%).
ROE vs Market: The company's ROE (8.88%) is lower than that of the market as a whole (9.37%).
5.5. ROA
ROA vs Sector: The company's ROA (6.22%) is higher than that of the sector as a whole (0.6587%).
ROA vs Market: The company's ROA (6.22%) is higher than that of the market as a whole (4.45%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-0.9289%) is lower than that of the sector as a whole (9.07%).
ROIC vs Market: The company's ROIC (-0.9289%) is lower than that of the market as a whole (8.75%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 3.27% is higher than the average for the sector '2.87%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 3.27% has been steadily paid over the past 7 years, DSI=0.86.
Weak dividend growth: The company's dividend yield 3.27% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (44.6%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
